Angiotensin II and norepinephrine release: Interaction and effects on the heart

Journal of Hypertension

Volumn 23, Issue 5, 2005, Pages 1077-1082

  Schlaich, Markus P ^a   Kaye, David M ^b   Lambert, Elisabeth ^b   Hastings, Jacqui ^b   Campbell, Duncan J ^c   Lambert, Gavin ^b   Esler, Murray D ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin II; Catecholamines; Hypertension; Left ventricular hypertrophy; Sympathetic

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY SINUS; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HUMAN; HYPERTENSION; ISOTOPE DILUTION ASSAY; MALE; NORADRENALIN RELEASE; PRIORITY JOURNAL; SYMPATHETIC TONE;

EID: 18344370087     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000166850.80344.cf     Document Type: Article

References (31)

1. Esler M, Zweifler A, Randall O, Julius S, DeQuattro V. The determinants of plasma-renin activity in essential hypertension. Ann Intern Med 1978; 88:746-752.
2. Clemson B, Gaul L, Gubin SS, Campsey DM, McConville J, Nussberger J, Zelis R. Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm. J Clin Invest 1994; 93:684-691.
3. Perondi R, Saino A, Tio RA, Pomidossi G, Gregorini L, Alessio P, et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation 1992; 85:2004-2013.
4. Saino A, Pomidossi G, Perondi R, Valentini R, Rimini A, Di Francesco L, Mancia G. Intracoronary angiotensin II potentiates coronary sympathetic vasoconstriction in humans. Circulation 1997; 96:148-153.
5. Goldsmith SR, Rector TS, Bank AJ, Garr M, Kubo SH. Effect of angiotensin II on noradrenaline release in the human forearm. Cardiovasc Res 1994; 28:663-666.
6. Rundqvist B, Eisenhofer G, Emanuelsson H, Albertsson P, Friberg P. Intracoronary blockade of angiotensin-converting enzyme in humans: interaction with cardiac sympathetic neurotransmission? Acta Physiol Scand 1997; 161:15-22.
7. Johansson M, Rundqvist B, Petersson M, Lambert G, Friberg P. Regional norepinephrine spillover in response to angiotensin-converting enzyme inhibition in healthy subjects. J Hypertens 2003; 21:1371-1375.
8. Guidelines Subcommittee 1. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17:151-183.
9. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083.
10. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy, comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
11. Marcus R, Krause L, Weder AB, Dominguez-Meja A, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation 1994; 90:928-936.
12. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 1990; 70:963-985.
13. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 1986; 32:2030-2033.
14. Lawrence AC, Evin G, Kladis A, Campbell DJ. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma. J Hypertens 1990; 8:715-724.
15. Danser AH, van Kats JP, Verdouw PD, Schalekamp MA. Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation 1997; 96:3795-3796.
16. Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001; 88:961-968.
17. Neri Serneri GG, Boddi M, Poggesi L, Simonetti I, Coppo M, Papa ML, et al. Activation of cardiac renin-angiotensin system in unstable angina. J Am Coll Cardiol 2001; 38:49-55.
18. Saino A, Pomidossi G, Perondi R, Morganti A, Turolo L, Mancia G. Modulation of sympathetic coronary vasoconstriction by cardiac renin-angiotensin system in human coronary heart disease. Circulation 2000; 101:2277-2283.
19. Zucker IH, Wang W, Pliquett RU, Liu JL, Patel KP. The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann NY Acad Sci 2001; 940:431-443.
20. Seravalle G, Cattaneo BM, Giannattasio C, Perondi R, Saino A, Grassi G, Mancia G. RAA system and cardiovascular control in normal subjects, hypertensives and patients with congestive heart failure. J Hum Hypertens 1993; 7(suppl 2):S13-S18.
21. Raasch W, Betge S, Dendorfer A, Bartels T, Dominiak P. Angiotensin converting enzyme inhibition improves cardiac neuronal uptake of noradrenaline in spontaneously hypertensive rats. J Hypertens 2001; 19:1827-1833.
22. Khairallah PA. Action of angiotensin on adrenergic nerve endings: inhibition of norepinephrine uptake. Fed Proc 1972; 31:1351-1357.
23. Lameris TW, de Zeeuw S, Duncker DJ, Alberts G, Boomsma F, Verdouw PD, van den Meiracker AH. Exogenous angiotensin II does not facilitate norepinephrine release in the heart. Hypertension 2002; 40:491-497.
24. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart. Circulation 1993; 88:472-480.
25. Bait JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Sympatho-inhibitory properties of various AT1 receptor antagonists. J Hypertens 2002; 20(suppl 5):S3-S11.
26. Schlaich MP, Klingbeil A, Hilgers K, Schobel HP, Schmieder RE. Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am Heart J 1999; 138:810-817.
27. Corea L, Bentivoglio M, Verdecchia P. Echocardiographic left ventricular hypertrophy as related to arterial pressure and plasma norepinephrine concentration in arterial hypertension. Reversal by atenolol treatment. Hypertension 1983; 5:837-843.
28. Kelm M, Schafer S, Mingers S, Heydthausen M, Vogt M, Motz W, Strauer BE. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients [see comments]. J Hypertens 1996; 14:1357-1364.
29. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-565.
30. Schunkert H, Hense HW, Muscholl M, Luchner A, Kurzinger S, Danser AH, Riegger GA. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997; 77:24-31.
31. Serneri GG, Modesti PA, Boddi M, Cecioni I, Paniccia R, Coppo M, et al. Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res 1999; 85:57-67.